💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Irbesartan

CHEMBL1513 Phase 4 Approuvé Small molecule
Half-Life
11-15 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
428.5 g/mol
LogP
4.1
Phase
4

This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

Masse moléculaire

428,5320 g/mol

LogP

4,10

TPSA

87,10 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Chronic Kidney Disease Stroke Hyperlipidemia Obesity Type 2 Diabetes Hypertension Hepatitis C Heart Failure Atrial Fibrillation Cardiovascular Disease

Classes de médicaments

C — C - Cardiovascular System

Mécanisme d'action

Selective non-competitive angiotensin II type 1 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 11-15 hours

Pharmacodynamics (PD)

Mécanisme

Selective non-competitive angiotensin II type 1 receptor antagonist.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H28N6O

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective non-competitive angiotensin II type 1 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Irbesartan: Half-life: 11-15 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Irbesartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1513.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3749.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.